Millie Das, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Sanofi/Genzyme
    Topic:
    lung cancer advisory board
    Date added:
    07/31/2023
    Date updated:
    03/05/2024
    Relationship end date:
    05/24/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Regeneron
    Topic:
    lung cancer advisory board
    Date added:
    07/31/2023
    Date updated:
    03/05/2024
    Relationship end date:
    12/01/2022
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Eurofins
    Topic:
    consulting
    Date added:
    07/31/2023
    Date updated:
    03/05/2024
    Relationship end date:
    04/13/2022
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Janssen
    Topic:
    lung cancer advisory board
    Date added:
    07/31/2023
    Date updated:
    03/05/2024
    Relationship end date:
    04/20/2022
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Astra Zeneca
    Topic:
    lung cancer educational program
    Date added:
    07/31/2023
    Date updated:
    03/05/2024
    Relationship end date:
    09/23/2022
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Merck
    Topic:
    KEYNOTE-867
    Date added:
    07/31/2023
    Date updated:
    03/05/2024
    Relationship end date:
    12/31/2023
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Genentech
    Topic:
    IMForte
    Date added:
    07/31/2023
    Date updated:
    03/05/2024
    Relationship end date:
    12/31/2023
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Novartis
    Topic:
    CANOPY-A
    Date added:
    07/31/2023
    Date updated:
    03/05/2024
    Relationship end date:
    04/24/2023
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    CellSight
    Topic:
    Ara-G clinical trial
    Date added:
    07/31/2023
    Date updated:
    03/05/2024
    Relationship end date:
    12/31/2023
Return to 2023 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes